.jpg "Theravance Biopharma (NASDAQ: TBPH)")
Today, a Director at Theravance Biopharma (NASDAQ: TBPH), Burton Malkiel, bought shares of TBPH for $22.54K.
This recent transaction increases Burton Malkiel’s holding in the company by 1.41% to a total of $1.65 million. In addition to Burton Malkiel, one other TBPH executive reported Buy trades in the last month.
See today’s analyst top recommended stocks >>
Based on Theravance Biopharma’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $8.32 million and GAAP net loss of $65.09 million. In comparison, last year the company earned revenue of $3.09 million and had a GAAP net loss of $65.32 million. Currently, Theravance Biopharma has an average volume of 158.7K. The Company has a Price to Book ratio of 19.8946.
Based on 4 analyst ratings, the analyst consensus is Strong Buy with an average price target of $42.75, reflecting a -46.2% downside. Starting in November 2017, TBPH received 9 Buy ratings in a row. Five different firms, including Cantor Fitzgerald and Evercore ISI, currently also have a Buy rating on the stock.
In the last 30 days, insiders have sold $758.9K worth of TBPH shares and purchased $22.54K worth of TBPH shares. The insider sentiment on Theravance Biopharma has been negative according to 66 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Theravance Biopharma, Inc. operates as a biopharmaceutical company, which focuses on the discovery, development and commercialization of small molecule medicines. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.
